News News Details

Ef Capital CEO Zhu Pai Receives the "2026 Top 40 Under 40 Best Direct Investment Fund Young Investor

Date: 2026-04-28
Views: 1

Today, the FOF Research Center officially released its "2026 40U40 Outstanding Young Investors" rankings. Zhu Pai, CEO of Ef Capital, has been honored with the "2026 Top 40 Under 40 (40U40) Best Direct Investment Fund Young Investor" award.

On the occasion of the upcoming Youth Day (May 4th), the FOF Research Center, supported by comprehensive data and in-depth research analysis, unveiled this significant ranking designed to encourage dedicated young professionals who quietly contribute to the private equity investment industry. Industry consensus traditionally holds that talent in investment follows a pyramid structure—the older, the more senior. However, with the full arrival of the digital and hard-tech era, on highly specialized tracks such as deep tech and biomedicine, a group of outstanding Chinese young investors are leveraging their solid expertise and precise forward-looking vision to identify investment targets with truly long-term value.

In this selection, the "Top 40 Under 40 Best Direct Investment Fund Young Investor" award focuses on evaluating the candidates' comprehensive performance in direct investment, including but not limited to the return rate of investment cases, insight into emerging technologies, empowerment capabilities for portfolio company ecosystems, and industry reputation.

Ef Capital CEO Zhu Pai is honored as:

2026 Top 40 Under 40 (40U40)
Best Direct Investment Fund Young Investor

Ef Capital CEO Zhu Pai Receives the

Ef Capital CEO Zhu Pai Receives the

Ef Capital CEO Zhu Pai Receives the

Ef Capital CEO Zhu Pai Receives the

Ef Capital CEO Zhu Pai Receives the

Mr. Zhu Pai has long focused on investment opportunities at the intersection of cutting-edge technology and life sciences, leading and participating in multiple projects with significant industry influence. His investment philosophy integrates deep industrial understanding with an international perspective, committed to driving key technological breakthroughs with capital. This is perfectly consistent with Ef Capital's mission: "Striving for Life Sciences."

Driven precisely by this philosophy and mission, the community of young investors represented by Mr. Zhu Pai is joining forces with young entrepreneurs to become a major force in changing the world. Against the backdrop of technological innovation increasingly becoming the core driving force of national development, this new generation of investors will continue to uphold professionalism and long-termism, uncovering genuine value in markets full of challenges and opportunities. Ef Capital will also continuously strengthen its investment research capabilities and ecosystem empowerment, supporting more exceptional startups in their growth, and injecting endless youthful energy into the prosperity of China's hard-tech industries.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务